中
2026-09-07
UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDY FOR OVERWEIGHT OR OBESITY IN CHINA
Learn More
2026-09-07
Significant Progress in Innovative Drug R&D and Continued Globalization Efforts Profit Attributable to Owners of the Company Reached Approximately RMB347.6 Million
Learn More
2026-08-12
FDA APPROVAL OF IND FOR THE GROUP’S PRODUCT UBT48128 TABLETS
Learn More
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
All News
Prev 1...34567...17 Next
Scan the Code to Follow Us
WeChat Official Account
WeChat Official Account
WeChat Channel
WeChat Channel
Copyright © 2025 TUL. All Rights Reserved. 粤ICP备17098416号-3 粤公网安备44040402000348号
WeChat<br/>Official<br/>Account
WeChat
Official
Account
To Top